Precigen, Inc. (PGEN)
 NASDAQ: PGEN · Real-Time Price · USD
 4.050
 +0.040 (1.00%)
  Oct 30, 2025, 4:00 PM EDT - Market closed
Precigen Employees
Precigen had 143 employees as of December 31, 2024. The number of employees decreased by 59 or -29.21% compared to the previous year.
Employees 
 143
Change (1Y) 
 -59
Growth (1Y) 
 -29.21%
Revenue / Employee 
 $30,350
Profits / Employee 
 -$870,629
Market Cap 
1.21B
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 143 | -59 | -29.21% | 
| Dec 31, 2023 | 202 | -7 | -3.35% | 
| Dec 31, 2022 | 209 | -302 | -59.10% | 
| Dec 31, 2021 | 511 | 34 | 7.13% | 
| Dec 31, 2020 | 477 | -380 | -44.34% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
PGEN News
- 17 days ago - Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis - PRNewsWire
- 2 months ago - Precigen Announces Up to $125 Million Non-Dilutive Financing - PRNewsWire
- 2 months ago - Precigen, Inc. - Special Call - Seeking Alpha
- 2 months ago - Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright - PRNewsWire
- 2 months ago - Undercovered Dozen: Precigen, ONEOK, Bitmine And More - Seeking Alpha
- 2 months ago - Precigen: This Billion-Dollar Approval Is Still Undervalued - Seeking Alpha
- 2 months ago - Why Is Precigen Stock Surging On Friday? - Benzinga
- 2 months ago - US FDA approves Precigen's immunotherapy for rare respiratory disease - Reuters